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To the Editor: B7lH1 (PDl
L1, CD274) is a T cell inhibitory 
molecule expressed in many types 
of cancer, leading to immune escape 
of tumor cells.1 Indeed, in previous 
studies Dermime and colleagues 
showed an association of B7lH1 
expression with highlrisk breast 
cancer patients.2l4 Anthracyclines 
rank amongst the most effective 
anticancer drugs ever developed,5 
in which doxorubicin is an essenl
tial component of treatment for 
breast cancer.6 Like many chemol
therapeutic drugs, anthracyclines 
kill cancer cells by direct cytotoxl
icity. However, there is accumulatl
ing evidence that these agents also 
have immunotherapeutic effects, 
through both innate and adapl
tive immune system.7 In a recent 
study, published in Breast Cancer 
Research, Dermime and colleagues8 
hypothesized that doxorubicin 
may have an immunomodulatory 
effect through downregulation of 
B7lH1 cell surface expression in 
breast cancer cells. They examined 
the effect of such chemotherapeul
tic agents on the expression level 
of B7lH1 in breast cancer cells. 
Among tested chemotherapeutic 
agents, they found that doxorubil
cin was the most effective in downl
regulating cell surface expression 
of B7lH1 in vitro. Interestingly, 
these results were validated in 
vivo in a xenograft mouse model, 
as well as in murine heart tissue 
known to constitutively express 
B7lH1. Surprisingly, they have 
found that doxorubicinldependent 
cell surface downregulation of B7l
H1 was accompanied by an upl
regulation of this molecule in the 
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cell nucleus. A direct relationship 
between AKT activation pathway 
and B7lH1 expression has been 
shown in previous studies where 
B7lH1 was shown to be a downl
stream target of AKT in cancer 
cells.9,10 Similarly, they have also 
observed that the reldistribution 
of B7lH1 in breast cancer cells was 
concomitant with a similar transl
location of phosphorylated AKT 
to the nucleus. Furthermore, inhil
bition of the PI3K/AKT pathway 
abrogated the doxorubicinlmedil
ated nuclear uplregulation of B7l
H1, suggesting an involvement 
of PI3K/AKT pathway in the 
nuclear uplregulation of B7lH1. 
Interestingly, siRNA knockldown 
of B7lH1 lead to an increase in 
spontaneous apoptosis, as well as 
doxorubicinlinduced apoptosis, 
indicating a novel antilapoptotic 
role for B7lH1 in breast cancer 
cells. Their novel discovery of the 
expression of B7lH1 in the nuclel
us of breast cancer cells suggests 
that B7lH1 has functions other 
than inhibition of T cells. The 
present findings by Dermime and 
colleagues explain the previously 
reported immunomodulatory efl
fect of anthracyclines on cancer 
cells, and provide a link between 
immunoresistance and chemorel
sistance in cancer and suggest the 
use of dual combinatorial agents 
to inhibit B7lH1 beside chemol
therapy in breast cancer patients. 
Downregulation of B7lH1 in 
heart tissue following doxorubicin 
treatment may render cardiac cells 
a potential target for autoimmunity 
and may explain the cardiomyotoxl
icity that is reported in patients rel
ceiving chemotherapy, which is an 
area for further investigation.
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